leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12345678910111213...235236»
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date:  Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Nov 14, 2024   
    P2,  N=83, Active, not recruiting, 
    Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026 Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
  • ||||||||||  Ampligen (rintatolimod) / AIM ImmunoTech
    Trial completion date, Trial primary completion date:  Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) -  Nov 14, 2024   
    P2,  N=90, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025 Trial completion date: Apr 2028 --> Jul 2028 | Trial primary completion date: Mar 2028 --> Jun 2028
  • ||||||||||  Trial completion date, Trial primary completion date:  TRIPP-FFX: FOLFIRINOX Versus OncoSil (clinicaltrials.gov) -  Nov 12, 2024   
    P2,  N=80, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Enrollment open:  The Sagittarius Trial (clinicaltrials.gov) -  Nov 12, 2024   
    P3,  N=700, Recruiting, 
    Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 Not yet recruiting --> Recruiting
  • ||||||||||  Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
    Trial completion, Metastases:  CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov) -  Nov 7, 2024   
    P3,  N=520, Completed, 
    Minimally invasive staged resection and intensified chemotherapy for the treatment of initially unresectable metastatic colorectal cancer should be performed by a skilled surgical team in coordination with a multidisciplinary team. Active, not recruiting --> Completed
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Journal, Real-world evidence, Head-to-Head, Real-world, Metastases:  Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study. (Pubmed Central) -  Nov 5, 2024   
    In those patients, adjuvant therapy and closer follow-up should be considered. This analysis included 1551 patients with advanced pancreatic cancer from the prospective, clinical cohort study Tumour Registry Pancreatic Cancer receiving FOLFIRINOX (n?=?613) or gemcitabine/nab-paclitaxel (GEMNAB; n?=?938) as palliative first-line treatment...The sequences were: FOLFIRINOX?GEMNAB, GEMNAB?FOLFOX/OFF and GEMNAB?nanoliposomal irinotecan (NALIRI)?+?5-fluorouracil...The estimated real-world effectiveness of the three treatment sequences evaluated were largely comparable.
  • ||||||||||  MK-1084 / Merck (MSD)
    Trial completion date, Trial primary completion date, Monotherapy:  A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) -  Nov 5, 2024   
    P1,  N=830, Recruiting, 
    This analysis included 1551 patients with advanced pancreatic cancer from the prospective, clinical cohort study Tumour Registry Pancreatic Cancer receiving FOLFIRINOX (n?=?613) or gemcitabine/nab-paclitaxel (GEMNAB; n?=?938) as palliative first-line treatment...The sequences were: FOLFIRINOX?GEMNAB, GEMNAB?FOLFOX/OFF and GEMNAB?nanoliposomal irinotecan (NALIRI)?+?5-fluorouracil...The estimated real-world effectiveness of the three treatment sequences evaluated were largely comparable. Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
  • ||||||||||  TTX-080 / Tizona Therap
    Enrollment open, Trial primary completion date, Monotherapy:  TTX-080-001: TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (clinicaltrials.gov) -  Nov 5, 2024   
    P1,  N=240, Recruiting, 
    Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027 Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Jun 2027
  • ||||||||||  Matulane (procarbazine hydrochloride) / Leadiant Biosci
    Price Monitoring of Anticancer Drugs Under Price Controlled Category in India () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1276;    
    Out of 31 drugs, price of Folinic acid, Procarbazine and Daunorubicin were not available and were not included in further analysis. Price of anticancer drugs under NLEM was monitored by NPPA and price of 78.57 percent was reduced to a maximum of 46.98 percent and price of the rest was increased to a maximum 26.08 during this period making antineoplastic drugs affordable by common people.
  • ||||||||||  ompenaclid (RGX-202) / Inspirna, EMD Serono
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov) -  Nov 4, 2024   
    P2,  N=70, Active, not recruiting, 
    This study protocol and amendments have been approved by the Ethics Committee of West China Hospital (2024(791)). Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Sep 2025
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, navitoclax (ABT 263) / AbbVie
    Enrollment change, Trial completion date, Trial primary completion date:  Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax (clinicaltrials.gov) -  Nov 3, 2024   
    P1/2,  N=35, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Sep 2025 N=98 --> 35 | Trial completion date: Jul 2029 --> Mar 2025 | Trial primary completion date: Aug 2025 --> Jun 2024
  • ||||||||||  Journal, Real-world evidence, BRCA Biomarker, Real-world:  Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications. (Pubmed Central) -  Nov 3, 2024   
    Treatment outcome analysis indicated that patients with BRCA1/2 mutations had a longer time to treatment discontinuation with FOLFIRINOX than gemcitabine plus nab-paclitaxel as first-line therapy (9.3 vs. 5.6?months, p?=?0.028)...Despite the lack of progression-free survival data and the inability to discriminate between germline and somatic mutations, this study provides valuable insights into the clinical implications of CGP in Japanese patients with PDAC. Further research is warranted to optimize panel selection and elucidate the efficacy of platinum-based therapies depending on the HRD status.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Do patient characteristics influence the first-line chemotherapy regimen for adenocarcinoma of the pancreas? (Room 9) -  Nov 3, 2024 - Abstract #COSA2024COSA_545;    
    Equity of treatment for pancreatic cancer patients is crucial for this aggressive disease, ensuring that all individuals achieve optimal outcomes. Although survival was very poor within the palliative care setting irrespective of the chemotherapy regimen received, our results show that people from lower socio-economic areas and First Nations people were less likely to receive more complex chemotherapy.
  • ||||||||||  Review, Journal:  Practice-changing clinical trials in gastrointestinal radiation oncology (Pubmed Central) -  Nov 2, 2024   
    The glucarpidase 2000 units capped dose was deemed efficacious as part of methotrexate toxicity management. For resectable esophageal adenocarcinoma, results of the ESOPEC study showed a benefit in overall survival from the perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin and docetaxel compared to chemoradiotherapy (41.4Gy radiotherapy and carboplatin/paclitaxel chemotherapy)...For rectal cancers, the 7-year update of PRODIGE 23 study confirmed the benefit in disease-free- and overall survival of neoadjuvant folinic acid, fluorouracil, irinotecan and oxaliplatin chemotherapy before chemoradiotherapy of T3, T4 or N+ adenocarcinoma, while the update of the RAPIDO study revealed an unacceptable local recurrence rate in the experimental arm...A phase 2 study, including 41